These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 6997548)

  • 1. [Blood coagulation and fibrinolysis in chronic myeloproliferative syndromes].
    Takahashi K; Shibata A
    Rinsho Ketsueki; 1980 May; 21(5):577-86. PubMed ID: 6997548
    [No Abstract]   [Full Text] [Related]  

  • 2. Profile of blood coagulation and fibrinolysis in chronic myeloproliferative disorders.
    Takahashi H; Hattori A; Shibata A
    Tohoku J Exp Med; 1982 Sep; 138(1):71-80. PubMed ID: 6959382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
    Murphy S; Davis JL; Walsh PN; Gardner FH
    Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet defects in the myeloproliferative disorders.
    Inceman S; Tangün Y
    Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
    [No Abstract]   [Full Text] [Related]  

  • 5. [Granulocyte clearance and granulocyte kinetics in myeloproliferative syndromes].
    Jungi WF; Meuret G; Senn HJ
    Schweiz Med Wochenschr; 1974 Jan; 104(4):133-5. PubMed ID: 4521299
    [No Abstract]   [Full Text] [Related]  

  • 6. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders.
    Brodsky I; Kahn SB; Ross EM; Petkov G
    Cancer; 1972 Dec; 30(6):1444-50. PubMed ID: 4509103
    [No Abstract]   [Full Text] [Related]  

  • 7. [Abnormal blood coagulation and fibrinolysis in chronic myeloproliferative disorders].
    Mamiya S; Itoh T; Endo Y; Miura AB
    Rinsho Ketsueki; 1991 May; 32(5):527-36. PubMed ID: 1870270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders.
    Tangün Y
    Thromb Diath Haemorrh; 1971 Jun; 25(2):241-51. PubMed ID: 5284903
    [No Abstract]   [Full Text] [Related]  

  • 10. Phagocytosis in myeloproliferative disorders.
    Corberand J; LaHarrague P; De Larrard B; Nguyen F; Pris J
    Am J Clin Pathol; 1980 Sep; 74(3):301-5. PubMed ID: 6932175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopathologic findings in the myeloproliferative disorders.
    Dickstein JI; Vardiman JW
    Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Determination of platelest factor III. (Total content and availability)].
    Scrobohaci ML
    Med Interna (Bucur); 1974 May; 26(5):623-32. PubMed ID: 4526294
    [No Abstract]   [Full Text] [Related]  

  • 13. The clinical significance of serum transcobalamins in myeloid leukemia and other myeloproliferative disorders.
    Rachmilewitz B; Rachmilewitz M
    Isr J Med Sci; 1977 Jul; 13(7):710-5. PubMed ID: 270474
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemoglobin abnormalities in neoplastic hematological disorders.
    Walker IR; Ali MA
    Can Med Assoc J; 1973 Apr; 108(7):843-7. PubMed ID: 4513360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.
    Ryningen A; Apelseth T; Hausken T; Bruserud Ø
    Platelets; 2006 Aug; 17(5):296-302. PubMed ID: 16928601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet function and arachidonate metabolism in patients with myeloproliferative disorders.
    Okuma M
    Nihon Ketsueki Gakkai Zasshi; 1980 Dec; 43(6):1139-44. PubMed ID: 6800179
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence for a platelet membrane defect in the myeloproliferative syndromes.
    Castaldi PA; Berndt MC; Booth W; Gregory C; Bull H; Greaves M
    Thromb Res; 1982 Sep; 27(5):601-9. PubMed ID: 6960545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood histamine in the differential diagnosis of myeloid splenomegaly (osteomyelofibrosis) and other myeloproliferative disorders.
    Gingold N
    Rev Roum Med; 1974; 12(1):15-8. PubMed ID: 4533361
    [No Abstract]   [Full Text] [Related]  

  • 19. Spontaneous platelet aggregation in myeloproliferative disorders. A preliminary study.
    Barbui T; Battista R; Dini E
    Acta Haematol; 1973; 50(1):25-9. PubMed ID: 4200801
    [No Abstract]   [Full Text] [Related]  

  • 20. Abnormal platelet serotonin uptake and binding sites in myeloproliferative disorders.
    Caranobe C; Sié P; Fernandez F; Pris J; Moatti S; Boneu B
    Thromb Haemost; 1984 Jul; 51(3):349-53. PubMed ID: 6593892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.